Data as of November 13, 2026

Epclusa 400 mg-100 mg Tablet

VELPATASVIR AND SOFOSBUVIR

Brand: Epclusa

Acquisition price (NADAC) is as of October 21, 2026. Medicaid reimbursement figures are from 2024, the most recent year in CMS's published claims data. The two are not contemporaneous — treat any comparison as directional, not exact.

Price per fill

NADAC (acquisition)
$24,219.75/ fill$864.99 / EA
VA Big4
$8,064.56/ fill$288.02 / EA
Medicaid FFS
$23,686.21/ fill
Medicaid MCO
$23,601.56/ fill

Sources: cms/nadac:price-ladder · va/fss-drug-prices:normalized · cms/sdud

What's in the reimbursement

Ingredient cost (28 units/fill)$24,219.75
Dispensing fee & other (state-fixed, not margin)-$533.54
Total reimbursed per fill$23,686.21

The gap above stays roughly flat across drugs regardless of acquisition cost — that's the professional dispensing fee, a fixed per-fill amount the state pays every pharmacy, not a markup.

Medicaid volume backing this card: 3 fee-for-service states, 5 managed-care states.

Full methodology and source columns: /tools/drug-prices/methodology

Sources: acquisition prices from CMS's National Average Drug Acquisition Cost survey, effective 2026-10-28; utilisation from CMS State Drug Utilization Data, 2024; Cost Plus Drugs prices from their published price list. NADAC and SDUD vintages differ. Every number links to how it was calculated. Full methodology